Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral Anticoagulants

NCT ID: NCT03320603

Last Updated: 2021-07-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

397 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-13

Study Completion Date

2020-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is assessing the impact of an expert eCRF on the management of severe bleeding in the administration of Prothrombin Complex Concentrate in patients treated with oral anticoagulants and adherence to recommendations or experts' consensus

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Emergency Care for Severe Bleeding While on Anticoagulants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phase 1

Prospective collection of data on a standard eCRF (without reminders of recommendations). Prothrombin Complex Concentrate given as standard of care.

Group Type OTHER

Prothrombin Complex Concentrate

Intervention Type OTHER

Prothrombin Complex Concentrate given as standard of care

Phase 2

Prospective collection of data on expert data collection tool (expert eCRF reminding recommendations at each step of the management of severe bleeding). Prothrombin Complex Concentrate given as standard of care.

Group Type OTHER

Expert eCRF

Intervention Type OTHER

An expert eCRF will be used to guide physicians during the management of patients treated with Vitamin K Agonist or Direct Oral Anticoagulant admitted in emergency units for severe bleeding.

Prothrombin Complex Concentrate

Intervention Type OTHER

Prothrombin Complex Concentrate given as standard of care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Expert eCRF

An expert eCRF will be used to guide physicians during the management of patients treated with Vitamin K Agonist or Direct Oral Anticoagulant admitted in emergency units for severe bleeding.

Intervention Type OTHER

Prothrombin Complex Concentrate

Prothrombin Complex Concentrate given as standard of care

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (≥ 18 years old)
* Receiving oral anticoagulants (VKA or DOAC)
* With a severe bleeding episode meeting at least one of the following criteria
* External hemorrhage which cannot be controlled by usual means or
* Hemodynamic instability: SBP \< 90 mmHg or SBP decrease

* 40 mmHg from usual SBP or mean BP \< 65 mmHg or any sign of shock or
* Patient requiring a hemostatic procedure in emergency:

surgery, interventional radiology, endoscopy or

* Need for transfusion of packed red blood cells or
* Hemorrhage jeopardizing the vital or functional prognosis:

e.g. intracranial hemorrhage, intraspinal hemorrhage, intraocular or retro-ocular hemorrhage, hemothorax, hemoperitoneum, retroperitoneal hemorrhage, hemopericardium, deep muscle hematoma or compartment syndrome, acute digestive hemorrhage, hemarthrosis.
* Admitted in the participating emergency service
* Accepting the collection of his/her own health-related data

Exclusion Criteria

* Patient participating in another interventional study
* Pregnant or nursing woman
* Patient under supervision or legal guardianship
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Octapharma

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier d'Avignon

Avignon, , France

Site Status

Centre Hospitalier Régional Universitaire de Besançon Hôpital Jean Minjoz

Besançon, , France

Site Status

Clinique Médipole Saint-Roch

Cabestany, , France

Site Status

Centre Hospitalier Universitaire de Caen Hôpital Côte de Nacre Service de Réanimation

Caen, , France

Site Status

Centre Hospitalier Universitaire de Caen Hôpital Côte de Nacre Service des Urgences

Caen, , France

Site Status

Centre Hospitalier Chalon-sur-Saône William Morey

Chalon-sur-Saône, , France

Site Status

Hôpitaux Civils de Colmar

Colmar, , France

Site Status

Hospices Civils de Lyon Hopital Edouard Herriot Service des Urgences

Lyon, , France

Site Status

Clinique du Tonkin

Lyon, , France

Site Status

Hospices Civils de Lyon Centre Hospitalier Lyon-Sud Service de Réanimation

Lyon, , France

Site Status

Hospices Civils de Lyon Centre Hospitalier Lyon-Sud Service des Urgences

Lyon, , France

Site Status

Centre Hospitalier Régional Metz-Thionville Hôpital Mercy

Metz, , France

Site Status

Centre Hospitalier Universitaire de Nantes Hôtel-Dieu

Nantes, , France

Site Status

Centre Hospitalier de Pau

Pau, , France

Site Status

Centre Hospitalier de Perpignan

Perpignan, , France

Site Status

Centre Hospitalier Universitaire de Reims Hôpital Maison Blanche

Reims, , France

Site Status

Centre Hospitalier Universitaire de Rennes Hôpital Pontchaillou

Rennes, , France

Site Status

Centre Hospitalier Universitaire de Rouen Hôpital Charles-Nicolle

Rouen, , France

Site Status

Centre Hospitalier Universitaire de Strasbourg Nouvel Hôpital Civil Service des Urgences

Strasbourg, , France

Site Status

Centre Hospitalier Universitaire de Strasbourg Hôpital de Hautepierre Service de Réanimation

Strasbourg, , France

Site Status

Centre Hospitalier Universitaire de Strasbourg Hôpital de Hautepierre Service des Urgences

Strasbourg, , France

Site Status

Hôpital d'Instruction des Armées Sainte-Anne

Toulon, , France

Site Status

Centre Hospitalier Universitaire de Toulouse Hôpitaux Purpan et Rangueil

Toulouse, , France

Site Status

Centre Hospitalier Régional Universitaire de Tours Hôpital Trousseau

Tours, , France

Site Status

Centre Hospitalier de Valence

Valence, , France

Site Status

Groupe Hospitalier de la Haute-Saône Site de Vesoul

Vesoul, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OPTIPLEX 2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

FIBrinogen REplenishment in Surgery
NCT03037424 COMPLETED PHASE3